一种类似肝脏的微流体模型用于抗药物的肝毒性评估
Ehsanollah Moradi1, Asieh Heirani-Tabasi2, Mohammad Adel Ghiass3
1Department of Biomedical Engineering, Amirkabir University of Technology (Tehran Polytechnic), Iran.
Biomedical physics & engineering express
|October 20, 2025
概括
本研究引入了一种简化的微流体肝脏模型,用于药物毒性测试. 这种肝芯片平台的动态培养条件改善了细胞功能和活力,为药物查提供了有用的工具.
科学领域:
- 生物医学工程 生物医学工程
- 毒理学 毒理学 毒理学
- 细胞生物学 细胞生物学
背景情况:
- 药物诱导性肝损伤 (DILI) 是药物消耗的主要原因之一.
- 现有的肝芯片模型很复杂;对于药物毒性测试,需要更简单的替代方案.
- 从生理学上相关的"体外"模型对于预测药物安全至关重要.
研究的目的:
- 开发和评估一个简化的微流体肝脏模型,用于比较静态和动态细胞培养条件.
- 评估这种肝芯片平台在药物诱导肝毒性测试中的实用性.
- 为了确定微流体装置的最佳流速.
主要方法:
- 设计了一种带有膜的双隔间微流体装置,以模仿肝脏微观结构.
- 使用计算建模来确定最佳流速 (50μL/h).
- 培养HepG2细胞,评估活力和代谢功能,并在静态和动态条件下测试抗药物的反应.
主要成果:
- 与静态条件相比,动态培养条件显著改善了HepG2细胞活力和代谢功能.
- 微流体肝脏模型成功地区分了由卡巴马泽,芬伊托因和酸诱导的肝毒性.
- 烯酸的毒性最小,而卡巴马西平和芬伊托因在一周内显著降低了肝功能.
结论:
- 简化的微流体肝芯片平台有效模拟动态肝脏状况,增强细胞功能.
- 该模型为药物查和肝毒性评估提供了一个有价值,不那么复杂的工具.
- 这些发现强调了动态培养参数在*体外*药物毒性评估中的重要性.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
273
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
273